vTv Therapeutics Secures Crucial Patent Allowance for Cadisegliatin
High Point, N.C. - Recently, vTv Therapeutics Inc. (NASDAQ: VTVT), a biopharmaceutical company specializing in diabetes treatment, shared significant news regarding their innovative therapy, cadisegliatin. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent covering various crystalline forms of cadisegliatin salts and co-crystals, ensuring protection until 2041.
Importance of Patent Allowance
Paul Sekhri, the CEO of vTv Therapeutics, expressed his satisfaction with the patent's allowance, stating how it reinforces the protection of cadisegliatin. This decision is a testament to the company's dedication to fostering innovation around their lead product and represents an important milestone in their journey.
Understanding Cadisegliatin
Cadisegliatin, also known as TTP399, is an oral medication designed to activate glucokinase selectively in the liver, positioning it as a potential first-in-class approach for treating Type 1 diabetes (T1D). Clinical investigations indicate that cadisegliatin enhances hepatic functionality, facilitating glucose handling and storage. This drug carries Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 evaluation in the CATT1 trial.
Future Implications for vTv Therapeutics
With cadisegliatin under investigation and the initial findings demonstrating promise, vTv Therapeutics is at a crucial juncture. Although the safety and effectiveness of cadisegliatin remain to be fully established, the patent allowance serves as a robust foundation for the company as they navigate regulatory pathways and aim for commercialization.
About vTv Therapeutics
vTv Therapeutics focuses on advancing small molecule drugs aimed at improving the lives of individuals with diabetes and other chronic conditions. Their dedicated approach is evident in their clinical pipeline, led by cadisegliatin’s promising Phase 3 trial. The company, in collaboration with several partners, is exploring additional therapeutics to address broad chronic disease challenges.
Contact Information
For more insights or inquiries, investors can connect with John Fraunces at LifeSci Advisors, LLC at 917-355-2395 or via email. Media inquiries can be addressed to Caren Begun at TellMed Strategies at 201-396-8551.
Frequently Asked Questions
What is cadisegliatin?
Cadisegliatin is a potential first-in-class oral therapy being investigated for Type 1 diabetes, designed to selectively activate glucokinase in the liver.
Why is the patent allowance important for vTv Therapeutics?
The patent allowance helps protect cadisegliatin, reinforcing the company’s efforts in innovation and increasing its competitive edge in the market.
What is the current status of cadisegliatin's clinical trials?
Cadisegliatin is currently being studied in a Phase 3 trial known as CATT1, where its efficacy and safety are being evaluated.
How long is the patent coverage valid?
The patent for cadisegliatin is protected until 2041, providing a solid timeframe for its commercial development.
What other projects is vTv working on?
In addition to cadisegliatin, vTv Therapeutics is investigating multiple molecules across various indications related to diabetes and chronic diseases.
